Dr. Srinivas Rao - CSO, atai Life Sciences - Transforming The Treatment Of Mental Health Disorders

Dr. Srinivas Rao, MD, Ph.D. is the Chief Scientific Officer at atai Life Sciences (https://www.atai.life/), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

With offices in New York, London and Berlin, atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapeutic moieties, and other drugs, with differentiated safety profiles and therapeutic potential.

Dr. Rao also serves as CEO of atai portfolio company, EntheogeniX (https://www.entheogenixbio.com/), a computational biophysics and artificial intelligence biotech working to design the next generation of psychedelics-inspired mental health drugs.

Dr. Rao has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to atai, Dr. Rao has held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture-backed startups to vertically-integrated, publicly-traded pharmaceutical companies.

Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. He received his Ph.D. in neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School, respectively.